Editor’s Note
**Editor’s Note:** A new SCIE-published study validates HIGHER Corporation’s HILO WAVE® formulation, demonstrating its ability to promote skin regeneration and remodeling without triggering an inflammatory response.
PRNewswire
2026.07.17 21:26
Image: HIGHER Corporation
HIGHER Corporation’s proprietary dual hyaluronic acid collagen-stimulating formulation HILO WAVE® has gained new scientific validation, with related preclinical research results officially published in the SCIE-indexed international journal International Journal of Molecular Sciences (IJMS).
Peer-reviewed preclinical study results validated the regenerative mechanism of HILO WAVE®’s proprietary Dual-HA Technology (DHC®).
July 16, 2026 /PRNewswire/ — HIGHER Corporation’s proprietary dual hyaluronic acid collagen-stimulating formulation HILO WAVE® has gained new scientific validation, with related preclinical research results officially published in the SCIE-indexed international journal International Journal of Molecular Sciences (IJMS).
HILO WAVE® is specifically developed for the regenerative aesthetics field, utilizing regenerative biostimulation technology to improve skin quality and create a naturally plump skin condition.
The product leverages HIGHER Corporation’s proprietary Dual Hyaluronic Acid Complex (DHC®), combining high-molecular-weight and low-molecular-weight hyaluronic acid to promote skin regeneration while minimizing inflammatory responses.
The published research paper, titled “Regenerative Skin Remodeling by a Dual Hyaluronic Acid Hybrid Complex in Multimodal Preclinical Models,” was conducted by an international collaborative research project led by the Department of Dermatology at Yonsei University Severance Hospital.
Unlike traditional collagen biostimulation methods that rely on localized inflammatory responses, this study explored the biological mechanism of DHC® and its ability to support regenerative skin remodeling through a biomaterial pathway.
Preclinical results showed: stable fibroblast viability, enhanced extracellular matrix (ECM) activity, improved antioxidant capacity, and better expression of skin barrier-related markers. Additionally, no significant inflammatory response was observed in animal models, further confirming the favorable biosafety profile of DHC®.
The findings indicate that DHC® modulates the skin microenvironment to promote collagen synthesis and tissue regeneration while minimizing unnecessary inflammation, providing scientific evidence for the regenerative mechanism of HILO WAVE®.
Building on this, HIGHER Corporation will host a HILO WAVE® Global Webinar on August 12, 2026, featuring evidence-based treatment protocols, live treatment demonstrations, and an interactive Q&A session led by Dr. Kyung Tae Bae.
The webinar is open to licensed medical practitioners.
For more information and registration, please visit:
https://higher-webinar.com/
HIGHER Corporation is a South Korea-based medical aesthetics company driving the advancement of regenerative aesthetics through proprietary technology, scientific research, and physician training programs. The company develops innovative aesthetic solutions while promoting evidence-based clinical practice through international education and training programs.
For more information, please visit: https://www.highercorp.co.kr/
Source: HIGHER Corporation